Patents by Inventor Mi Deng

Mi Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210179687
    Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 17, 2021
    Inventors: Chengcheng ZHANG, Samuel JOHN, Heyu CHEN, Mi DENG, Xun GUI, Ningyan ZHANG, Zhiqiang AN
  • Patent number: 11013704
    Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: May 25, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Chengcheng Zhang, Yi Liu, Junke Zheng, Mi Deng, Chuo Chen, Jiawei Liu
  • Publication number: 20200079851
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 12, 2020
    Inventors: Chengcheng ZHANG, Mi DENG, Wei XIONG, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Junke ZHENG
  • Patent number: 10501538
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: December 10, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chengcheng Zhang, Mi Deng, Wei Xiong, Zhiqiang An, Ningyan Zhang, Xun Gui, Junke Zheng
  • Publication number: 20190338026
    Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
    Type: Application
    Filed: January 2, 2018
    Publication date: November 7, 2019
    Inventors: X. Charlene LIAO, Qiang LIU, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Chengcheng ZHANG, Mi DENG, Jingjing XIE
  • Publication number: 20190330593
    Abstract: The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 31, 2019
    Applicants: Fred Hutchinson Cancer Research Center, Board of Regents of the University of Texas System
    Inventors: Irwin D. Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng
  • Patent number: 10370643
    Abstract: The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 6, 2019
    Assignees: Fred Hutchinson Cancer Research Center, Board of Regents of the University of Texas System
    Inventors: Irwin D. Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng
  • Publication number: 20180086829
    Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 29, 2018
    Inventors: Chengcheng ZHANG, Mi DENG, Wei XIONG, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Junke ZHENG
  • Publication number: 20170304240
    Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.
    Type: Application
    Filed: May 12, 2015
    Publication date: October 26, 2017
    Inventors: Chengcheng ZHANG, Yi LIU, Junke ZHENG, Mi DENG, Chuo CHEN, Jiawei LIU
  • Publication number: 20170260508
    Abstract: The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.
    Type: Application
    Filed: May 21, 2015
    Publication date: September 14, 2017
    Inventors: Irwin D. Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng